After the detection of RET fusions, the patient first received the treatment with a multikinase inhibitor lenvatinib, but the efficacy was limited, it similar with outcome of clinic trials, In phase 2 trials, cabozantinib and lenvatinib showed low response rates (ORR: 16%–28%, mPFS: 7.3 months).[9] A retrospective multicenter registry analysis showed response rates ranging from 18% to 37%.[10] Owing to the low activity and toxicity concerns with multikinase inhibitors, it is not recommended for the treatment of NSCLC with RET fusion. This evidence concerns the gene RET and non-small cell lung carcinoma.